52 related articles for article (PubMed ID: 17934830)
1. Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of Life.
Takeshima F; Hashiguchi K; Onitsuka Y; Tanigawa K; Minami H; Matsushima K; Akazawa Y; Shiozawa K; Yamaguchi N; Taura N; Ohnita K; Ichikawa T; Isomoto H; Nakao K
Med Sci Monit; 2015 Dec; 21():4111-21. PubMed ID: 26719012
[TBL] [Abstract][Full Text] [Related]
2. Metabolomics coupled with multivariate data and pathway analysis on potential biomarkers in gastric ulcer and intervention effects of Corydalis yanhusuo alkaloid.
Tianjiao L; Shuai W; Xiansheng M; Yongrui B; Shanshan G; Bo L; Lu C; Lei W; Xiaorong R
PLoS One; 2014; 9(1):e82499. PubMed ID: 24454691
[TBL] [Abstract][Full Text] [Related]
3. Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers.
Wang Y; Yuan Y; Meng L; Fan H; Xu J; Zhang H; Wang M; Yuan H; Ou N; Zhang H; Chao Y; Shi R
Eur J Clin Pharmacol; 2011 Jan; 67(1):25-31. PubMed ID: 21110014
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers.
Wang Y; Zhang H; Meng L; Wang M; Yuan H; Ou N; Zhang H; Li Z; Shi R
Eur J Clin Pharmacol; 2010 Jun; 66(6):563-9. PubMed ID: 20414645
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan.
Mizokami Y
World J Gastroenterol; 2009 Oct; 15(40):5097-102. PubMed ID: 19860005
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of pharmacogenomic tests in 2009.
Sheffield LJ; Phillimore HE
Clin Biochem Rev; 2009 May; 30(2):55-65. PubMed ID: 19565025
[TBL] [Abstract][Full Text] [Related]
7. CYP2C19 genotype and the PPIs--focus on rabeprazole.
Lim PW; Goh KL; Wong BC
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
[TBL] [Abstract][Full Text] [Related]
8. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Horn J
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
[TBL] [Abstract][Full Text] [Related]
9. Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype.
Ando T; Ishikawa T; Kokura S; Naito Y; Yoshida N; Yoshikawa T
Dig Dis Sci; 2008 Apr; 53(4):933-7. PubMed ID: 17934830
[TBL] [Abstract][Full Text] [Related]
10. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.
Ando T; Kato H; Sugimoto N; Nagao Y; Seto N; Hongo H; Kajikawa H; Isozaki Y; Shimozawa M; Naito Y; Yoshida N; Ishizaki T; Yoshikawa T
Dig Dis Sci; 2005 Sep; 50(9):1625-31. PubMed ID: 16133961
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
Lee SB; Park SJ; Ryu JK; Lee JK; Kim HJ; Bae JS; Jung HS; Park SM
Korean J Gastroenterol; 2003 Dec; 42(6):468-75. PubMed ID: 14695703
[TBL] [Abstract][Full Text] [Related]
12. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
Hokari K; Sugiyama T; Kato M; Saito M; Miyagishima T; Kudo M; Nishikawa K; Ishizuka J; Komatsu Y; Mizushima T; Kagaya H; Hige S; Takeda H; Asaka M
Aliment Pharmacol Ther; 2001 Sep; 15(9):1479-84. PubMed ID: 11552922
[TBL] [Abstract][Full Text] [Related]
14. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
[TBL] [Abstract][Full Text] [Related]
15. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]